Improvements in Progression-Free and Overall Survival Due to the Use of Anti-Angiogenic Agents in Gynecologic Cancers

Gynecologic Cancers (RJ Morgan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers

Opinion statement

In ovarian cancer (OC), the best established anti-angiogenic drug, bevacizumab, has demonstrated only modest prolonged progression free survival (PFS) and no increased overall survival (OS). The unanswered question is in which clinical situation bevacizumab might benefit ovarian cancer patients most. The cost-benefit analysis in the primary treatment was found not to be favorable but the use in the recurrent OC setting might be more compelling. Multi-targeted anti-angiogenic tyrosine kinase inhibitors (TKI) such as cediranib and pazopanib have shown some therapeutic benefits with improvements of PFS and OS in patients with platinum-sensitive as well as resistant OC, in whom there is a major need for novel therapies. Very promising is also the observed improvement of PFS in recurrent OC in patients when combining cediranib with the PARP inhibitor olaparib without giving additional chemotherapy. The anti-angiogenic agent trebananib has achieved similar results like TKI, but has a favorable toxicity profile which does not overlap with those of VEGF inhibitors. In cervical cancer the addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent or metastatic chemotherapy-naive disease results in a significant increase in OS. Considering the lack of therapeutic options in this difficult clinical setting, the inclusion of bevacizumab most likely will become a new standard for recurrent cervical cancer. In uterine sarcomas as very aggressive malignancies with a substantial need for better therapies the observed improved PFS with sorafenib warrants further investigation. No data showing a convincing improvement of survival in endometrial cancer have been presented yet. In view of the limited PFS and OS benefit observed with anti-angiogenics in gynecologic oncology, increased morbidity due to side effects of this treatment resulting in loss of quality of life and also substantial costs have to be taken into consideration. Thorough case selection based on molecular subgrouping of gynecologic cancers will therefore be a prerequisite for future anti-angiogenic therapy. This will require the integration of molecular diagnostics which still have to be developed and standardized.

Keywords

gynecologic cancers ovarian cancer cervical cancer endometrial cancer uterine sarcomas angiogenesis inhibitors bevacizumab tyrosine kinase inhibitors trebananib survival 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ferlay J, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.Google Scholar
  2. 2.
    Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas. 2014;77(2):128–36. doi:10.1016/j.maturitas.2013.11.009.CrossRefPubMedGoogle Scholar
  3. 3.
    Oehler MK, Bicknell R. The promise of anti-angiogenic cancer therapy. Br J Cancer. 2000;82(4):749–52. doi:10.1054/bjoc.1999.0991.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841–4. doi:10.1038/362841a0.CrossRefPubMedGoogle Scholar
  5. 5.
    Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180–6. doi:10.1200/JCO.2007.12.0782.CrossRefPubMedGoogle Scholar
  6. 6.
    Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci U S A. 2008;105(47):18513–8. doi:10.1073/pnas.0807967105.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Wong AK, Alfert M, Castrillon DH, Shen Q, Holash J, Yancopoulos GD, et al. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci U S A. 2001;98(13):7481–6. doi:10.1073/pnas.121192298.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.••
    Liu J, Birrer M, Lee J, Buckanovich R, Fleming G, Rimel B, et al. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. 2014 ASCO Annual Meeting J Clin Oncol 32:5s, 2014 (suppl; abstr LBA5500). 2014. This randomized phase 2 trial Combined cediranib/olaparib in plat-sensitive ovarian cancer patients and showed a significantly extended PFS compared to olaparib alone.Google Scholar
  9. 9.
    Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology. 2005;19(4 Suppl 3):7–16.PubMedGoogle Scholar
  10. 10.••
    Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. doi:10.1056/NEJMoa1104390. This study showed that bevacizumab given for up to 10 months after carboplatin and paclitaxel chemotherapy prolongs the median progression-free survival by about 4 months in patients with advanced epithelial ovarian cancer.CrossRefPubMedGoogle Scholar
  11. 11.••
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. doi:10.1056/NEJMoa1103799. This study presents the data of the ICON 7 study, a phase 3 trial of bevacizumab in the first-line treatment of ovarian cancer. Bevacizumab improved PFS and the benefits were greater among those at high risk for disease progression.CrossRefPubMedGoogle Scholar
  12. 12.•
    Oza AM, Perren TJ, Swart AM, Schröder W, Pujade-Lauraine E, Havsteen H, et al. ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. European Cancer Congress 2013. 2013. [Abstract number: 6]. This abstract provides the final survival data of the ICON7 trial that did not show a significantly improved OS.Google Scholar
  13. 13.
    Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013;14(3):236–43. doi:10.1016/S1470-2045(12)70567-3.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Gourley C, McCavigan A, Perren T, Paul J, Michie CO, Churchman M, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol. 32:5s, 2014 (suppl; abstr 5502).CrossRefGoogle Scholar
  15. 15.•
    Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8. doi:10.1200/JCO.2013.51.4489. The AURELIA trial supports the addition of bevacizumab to palliative chemotherapy for patients with platinum-resistant ovarian cancer based on the significant improvement in PFS.CrossRefPubMedGoogle Scholar
  16. 16.••
    Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45. doi:10.1200/JCO.2012.42.0505. This study describes the efficacy and safety of bevacizumab in platinum-sensitive recurrent ovarian cancer. The addition of bevacizumab to chemotherapy resulted in a statistically significant improvement in PFS.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Aghajanian C, NycumNL, Goff B, Husain A, Blank SV. Updated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine + carboplatin and bevacizumab or placebo followed by bevacizumab or placebo in platinum-sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer. ESMO annual meeting. Vienna: 2012.Google Scholar
  18. 18.
    Comfort C. The majority of surveyed oncologists prescribe avastin off-label to their ovarian cancer patients: however, approximately half encounter access and reimbursement hurdles. 2013. (http://decisionresources.com/News-and-Events/Press-Releases/Ovarian-and-Endometrial-Cancer-081413).
  19. 19.
    Schefter T, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2014;88(1):101–5. doi:10.1016/j.ijrobp.2013.10.022.CrossRefPubMedGoogle Scholar
  20. 20.
    Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27(7):1069–74. doi:10.1200/JCO.2008.18.9043.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.••
    Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–43. doi:10.1056/NEJMoa1309748. In this study the addition of bevacizumab to combination chemotherapy in patients with cervical cancer demonstrated an improvement of 3.7 months in median OS.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–65. doi:10.1200/JCO.2010.32.6397.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(1):22–7. doi:10.1016/j.ygyno.2012.12.022.CrossRefPubMedGoogle Scholar
  24. 24.
    Eichbaum M, Mayer C, Eickhoff R, Bischofs E, Gebauer G, Fehm T, et al. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer. 2011;11:453. doi:10.1186/1471-2407-11-453.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32–7. doi:10.1016/j.ygyno.2010.05.033.CrossRefPubMedGoogle Scholar
  26. 26.•
    Du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, et al. Randomized, double-blind, phase III trial of pazopanib vs placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol 31, 2013 (suppl; abstr LBA5503). This abstract describes the use of an oral multikinase inhibitor (Pazopanib) in the maintenance therapy of ovarian cancer patients after first-line chemotherapy. A significant and clinically meaningful PFS benefit was demonstrated.Google Scholar
  27. 27.•
    Pignata S, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, et al. MITO-11: a randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC). J Clin Oncol. 32:5s, 2014 (suppl; abstr 5503^). 2014. This phase 2 trial shows that the addition of pazopanib to weekly paclitaxel in the treatment of patients with platinum-resistant or refractory advanced ovarian cancer might produce a significant prolongation of PFS and OS.CrossRefGoogle Scholar
  28. 28.
    Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28(22):3562–9. doi:10.1200/JCO.2009.26.9571.CrossRefPubMedGoogle Scholar
  29. 29.
    Monk BJ, Pandite LN. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2011;29(36):4845. doi:10.1200/JCO.2011.38.8777.CrossRefPubMedGoogle Scholar
  30. 30.•
    Laure I, Coquard R, Litière S, Blay J, Cesne A, Papai Z, et al. Pazopanib in uterine sarcoma (UtS): review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS). J Clin Oncol. 32:5s, 2014 (suppl; abstr 10579). 2014. This retrospective analysis of 2 EORTC trials shows a benefit of pazopanib in uterine sacromas.CrossRefGoogle Scholar
  31. 31.
    Medical Research Council. An RCT of concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer. http://ClinicalTrials.gov/show/NCT00532194. 2011.
  32. 32.•
    Ledermann J, Perren TJ, Raja FA, Embleton A, Rustin GJS, Jayson G, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. European Cancer Congress 2013 (ECCO-ESMO-ESTRO); 2013 30.09.2013. ICON 6 trial was the first trial to demonstrate a significant improvement in PFS and OS of patients with recurrent platinum sensitive ovarian cancer in response to the oral VEGF tyrosine kinase inhibitor cediranib.Google Scholar
  33. 33.
    Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014;132(2):496–505. doi:10.1016/j.ygyno.2013.11.029.CrossRefPubMedGoogle Scholar
  34. 34.
    University of Glasgow. Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery. http://ClinicalTrials.gov/show/NCT01229930. 2012.
  35. 35.•
    Du Bois A, Kristensen G, Ray Coquard I, Reuss A, Pignata S, Colombo N, et al. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy+/− nintedanib for advanced ovarian cancer. Int J Gynaecol Cancer. 2013;23(8). This randomized, placebo-controlled phase III trial of standard carboplatin and paclitaxel with or without the trifunctional angiokinase inhibitor nintedanib revealed a longer PFS of the nintedanib arm.Google Scholar
  36. 36.
    Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884–96. doi:10.1200/JCO.2006.06.3602.CrossRefPubMedGoogle Scholar
  37. 37.
    Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol. 2011;22(2):335–40. doi:10.1093/annonc/mdq357.CrossRefPubMedGoogle Scholar
  38. 38.
    Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010;116(2):163–7. doi:10.1016/j.ygyno.2009.08.012.CrossRefPubMedGoogle Scholar
  39. 39.
    Castonguay V, Lheureux S, Welch S, Mackay HJ, Hirte H, Fleming G, et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol. 2014.134(2):274–80. doi:10.1016/j.ygyno.2014.05.016.
  40. 40.
    Santoro A, Comandone A, Basso U, Soto Parra H, De Sanctis R, Stroppa E, et al. Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. Ann Oncol. 2013;24(4):1093–8. doi:10.1093/annonc/mds607.CrossRefPubMedGoogle Scholar
  41. 41.
    Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost JA, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010;117(1):37–40. doi:10.1016/j.ygyno.2010.01.013.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Leone R, Maggiore U, Valenzano Menada M, Venturini PL, Ferrero S. Sorafenib for ovarian cancer. Expert Opin Investig Drugs. 2013;22(8):1049–62. doi:10.1517/13543784.2013.802769.CrossRefGoogle Scholar
  43. 43.
    Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273–86. doi:10.1038/nrd2115.CrossRefPubMedGoogle Scholar
  44. 44.••
    Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(8):799–808. doi:10.1016/S1470-2045(14)70244-X. This trial showed that addition of trebananib to single-agent weekly paclitaxel in patients with recurrent epithelial ovarian cancer improved progression-free survival.CrossRefPubMedGoogle Scholar
  45. 45.
    Muthuramalingam SR, Braybrooke JP, Blann AD, Madhusudan S, Wilner S, Jenkins A, et al. A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. Eur J Gynaecol Oncol. 2011;32(3):253–8.PubMedGoogle Scholar
  46. 46.
    McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;105(2):508–16. doi:10.1016/j.ygyno.2007.01.019.CrossRefPubMedCentralPubMedGoogle Scholar
  47. 47.
    McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, et al. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;127(2):356–61. doi:10.1016/j.ygyno.2012.07.095.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Gynecological OncologyRoyal Adelaide HospitalAdelaideAustralia
  2. 2.Discipline Obstetrics and Gynecology, School of Paediatrics and Reproductive Health, Robinson Research InstituteUniversity of AdelaideAdelaideAustralia

Personalised recommendations